Recruiting

Observational Study

Sponsor:

Center for International Blood and Marrow Transplant Research

Code:

NCT01166009

Conditions

Autologous Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

Solid Tumors

Blood Cancers

CAR-T

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.

A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.

Objectives:

To learn more about what makes stem cell transplants and cellular therapies work well such as:

  • Determine how well recipients recover from their transplants or cellular therapy;
  • Determine how recovery after a transplant or cellular therapy can be improved;
  • Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;
  • Determine how access to transplant or cellular therapy for different groups of patients can be improved;
  • Determine how well donors recover from the collection procedures.

Conditions

Autologous Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

Solid Tumors

Blood Cancers

CAR-T

Study ID

NCT01166009

Start date

Jul, 2002

Status verified date

Aug, 2025

Completion date

Jul, 2050

Anticipated

Primary completion date

Jul, 2050

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Eligibility to Participate in the Research Database

Recipient Eligibility Criteria:

  • Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children.

Individual with Marrow Toxic Injury Eligibility Criteria:

  • Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR.

Unrelated Donor Eligibility Criteria:

  • All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database.
  • All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.

Study Design

Enrollment

99999999 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • A Comprehensive Source of Observational Data to assess Stem Cell Transplant [ Time Frame: Anually - on average ]

Central Contacts and Locations

Central contacts

Leigh Anne Blackmon

763 406 8087databaseIRB@nmdp.org

Locations

Center for International Blood and Marrow Transplant Research

Recruiting

Minneapolis, Minnesota, United States, 55413

Contacts

Brandan Butler

DatabaseIRB@NMDP.org

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Brandan Butler

DatabaseIRB@nmdp.org

More Information

Sponsor

Center for International Blood and Marrow Transplant Research

Last update posted

Aug 12, 2025

Last verified

Aug, 2025

Keywords

  • Data Collection
  • CIBMTR
  • NMDP
  • Stem Cell Transplantation
  • Gene Therapy
  • CAR-T

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Center for International Blood and Marrow Transplant Research on 2025-08-12.